Evidence map›Paper›PMID 37585914›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2023

Chelidonine reduces IL-1β-induced inflammation and matrix catabolism in chondrocytes and attenuates cartilage degeneration and synovial inflammation in rats.

Mao Li, Ying Zhu, Jiajia Shao, Chuanbing Wang, Bin Dong, Haiyong Cui, Dongdong Dai

Open access · goldAbstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Plants (Basel, Switzerland) · 2025
    Review
  4. The Herbal PairFood science & nutrition · 2025
    Article
  5. Chelidonine inhibits melanoma cell malignancy by inactivating TLR4/NF-κB and PI3K/AKT signaling pathways.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  6. Article
  7. Review
  8. Alkaloids inFrontiers in pharmacology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mao LiDepartment of Orthopaedics, The First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, Anhui, China.ORCID http://orcid.org/0009-0001-9146-4868
Ying ZhuDepartment of Stomatology, The First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, Anhui, China.ORCID http://orcid.org/0009-0005-3538-3894
Jiajia ShaoDepartment of Orthopaedics, Huainan Chaoyang Hospital, Huainan, Anhui, China.ORCID http://orcid.org/0009-0004-4574-7121
Chuanbing WangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, Anhui, China.ORCID http://orcid.org/0009-0009-0923-3832
Bin DongDepartment of Orthopaedics, The First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, Anhui, China.ORCID http://orcid.org/0009-0004-3017-4623
Haiyong CuiDepartment of Orthopaedics, The First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, Anhui, China.ORCID http://orcid.org/0009-0007-9567-5041
Dongdong DaiDepartment of Orthopedics, Huainan Oriental Hospital Group Affiliated to Anhui University of Science and Technology, Huainan, Anhui, China.ORCID http://orcid.org/0000-0003-0278-9765
Anhui University of Science and Technology · CNHuainan Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chondrocyte inflammation and catabolism are two major features in the progression of osteoarthritis (OA). Chelidonine, a principal alkaloid extracted from Chelidonium majus, is suggested to show anti-inflammation, anti-apoptosis, and anti-oxidation activities in various diseases. However, its potential effects on OA cartilage degeneration remains unclear. To evaluate the effect of chelidonine on OA and its underlying mechanism, we incubated chondrocytes with interleukin (IL)-1β and chelidonine at varying concentrations. Then, we performed the CCK-8 assay, fluorescence immunostaining, reverse transcription PCR, ELISA, and western blotting to evaluate cell viability, catabolic/inflammatory factors, levels of extracellular matrix (ECM)-related proteins, and the involved pathways. H&E and Safranin-O staining and ELISA were performed to measure cartilage degradation and synovial inflammation. Chelidonine suppressed the IL-1β-mediated catabolism and inflammation of chondrocytes. Chelidonine suppressed the NF-κB pathway activation. Similarly, our in vivo experiment showed that chelidonine partially attenuated cartilage degradation while inhibiting synovial inflammation. Chelidonine inhibited inflammation and catabolism through modulation of NF-κB pathways in vitro, thereby avoiding rat cartilage degeneration and synovial inflammation within OA.

Indexed as

ChondrocytesOsteoarthritisAnimalsBenzophenanthridinesCartilageInflammationInterleukin-1betaNF-kappa BRatsBenzophenanthridineschelidonineInterleukin-1betaNF-kappa B

Identifiers

PMID37585914
PMCPMC10427162
OpenAlexW4385818009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.